John Mendelson

John Mendelson

John Jakob Mendelson, putra dari orang tua Polandia, lahir pada tahun 1917. Setelah menyelesaikan pendidikannya di Universitas London, ia menjadi pekerja pabrik.

Mendelson bertugas di Angkatan Darat Inggris selama Perang Dunia Kedua. Setelah perang ia mengajar ilmu politik di Universitas Sheffield (1949-59).

Seorang anggota Partai Buruh ia terpilih untuk mewakili Penistone dalam Pemilihan Umum 1959. Di House of Commons Mendelson terkait dengan sekelompok anggota sayap kiri yang mencakup Konni Zilliacus, Ian Mikardo, Kastil Barbara, Sydney Silverman, Geoffrey Bing dan Emrys Hughes.

Pada tahun 1965 Mendelson bergabung dengan Michael Foot, Konni Zilliacus, William Warbey, Russell Kerr, Anne Kerr, Norman Atkinson, Stan Newens, dan Sydney Silverman dalam memprotes intervensi Amerika di Vietnam. Namun, Mendelson dan teman-temannya tidak dapat membujuk perdana menteri Partai Buruh, Harold Wilson, untuk mengutuk kebijakan AS di Vietnam.

John Jakob Mendelson meninggal pada 20 Mei 1978.


John Mendelsohn: Seorang ilmuwan visioner, ahli onkologi dan pemimpin

Dr John Mendelsohn dikreditkan untuk konsep penargetan reseptor faktor pertumbuhan epidermal (EGFR), memberikan bukti pertama aktivitas antikanker antagonis anti-EGFR mAb, dan mengembangkan obat Erbitux (Cetuximab) untuk pasien kanker. Selama perjalanan profesionalnya, Dr. Mendelsohn juga membantu membangun dan meningkatkan status tiga kanker kanker, sambil menyentuh kehidupan pasien kanker di seluruh dunia. Dia adalah sosok yang menjulang tinggi, dan kematiannya pada Januari 2019 memberikan bayangan yang sangat panjang di seluruh bidang penelitian dan pengobatan kanker. Meskipun tidak ada satu orang pun yang dapat secara memadai mengisi posisi John Mendelsohn yang sangat besar, kita semua dapat belajar dari teladannya yang luar biasa. Di sini kita membahas kehidupan profesional Dr. Mendelsohn untuk menyoroti pengaruhnya pada onkologi dan juga berbagi refleksi pribadi dari kami dan beberapa rekan: Tony Hunter, Robert A. Weinberg, Robert C. Bast, Raymond Sawaya, David M. Gershenson, Christopher J Logothetis, Stanley R. Hamilton, Mien-Chie Hung, dan George M. Stacel. Lihat artikel terkait Kumar dkk. Bisa Res 2019 79:4315-4323.


John Mendelsohn, mantan presiden MD Anderson, meninggal pada usia 82 tahun

1 dari 44 Dr. John Mendelsohn, presiden MD Anderson Cancer Center dari tahun 1996 hingga 2011, berpose untuk potret ini di kantornya pada tahun 2003. Mendelsohn, ilmuwan terkemuka dan arsitek di balik kemunculan MD Anderson sebagai pusat kanker top dunia, meninggal dunia Senin malam kanker otak. Buster Dean, STAFF / HOUSTON CHRONICLE Tampilkan Lebih Banyak Tampilkan Lebih Sedikit

Michael Wyke/For the Chronicle Tampilkan Lebih Banyak Tampilkan Lebih Sedikit

Luis Valbuena, baseman ketiga yang berperan penting dalam tim Wild Card Astros 2015, meninggal dalam kecelakaan mobil di negara asalnya Venezuela pada 6 Desember 2018, bersama dengan sesama mantan pemain Astros, Jose Castillo. Valbuena menjadi terkenal karena bat flipsnya setelah penampilan piring yang sukses dan senyum menular. Dia memainkan 222 pertandingan karir untuk Astros. (Foto: Karen Warren/Houston Chronicle)

Karen Warren/Houston Chronicle Tampilkan Lebih Banyak Tampilkan Lebih Sedikit

George Herbert Walker Bush, yang masa jabatannya sebagai presiden ke-41 Amerika Serikat mengantarkan hari-hari terakhir Perang Dingin dan mengabadikan dinasti politik keluarga yang memengaruhi politik Amerika di tingkat nasional dan negara bagian selama beberapa dekade, meninggal di rumahnya di Houston pada 30 November 2018. Dia berusia 94 tahun.

Pendiri dan pemilik Houston Texas Bob McNair meninggal 23 November 2018. Dia berusia 81 tahun.

Brett Coomer/Houston Chronicle Tampilkan Lebih Banyak Tampilkan Lebih Sedikit

Aktivis gay dan tokoh radio Ray Hill meninggal 24 November 2018, karena gagal jantung dalam perawatan rumah sakit. Dia berusia 78 tahun.

Kevin Fujii, Staf fotografer / Houston Chronicle Tampilkan Lebih Banyak Tampilkan Lebih Sedikit

Louis H. Jones Jr., seorang eksekutif Dannenbaum Engineering berpangkat tinggi di Texas Selatan dan subjek penyelidikan FBI, meninggal karena bunuh diri 22 Oktober 2018, kata kerabat.

Henri Gadbois, pelukis lanskap yang juga melukis bluebonnet, meninggal 13 Oktober 2018.

Bill Olive/For the Chronicle Tampilkan Lebih Banyak Tampilkan Lebih Sedikit

Clarence Brandley, mantan petugas kebersihan Sekolah Menengah Conroe yang secara salah dihukum karena pembunuhan brutal terhadap seorang gadis berusia 16 tahun pada tahun 1981, menghabiskan hampir 10 tahun di hukuman mati sebelum dia dibebaskan karena pelanggaran hak proses hukumnya. Dia meninggal pada usia 66 pada 2 September 2018.

John Bisagno, selama bertahun-tahun salah satu pendeta paling terkasih di Houston yang dikenal karena semangatnya untuk menjangkau, suara yang menggelegar dan kemauan untuk mengatasi kebenaran yang sulit, meninggal 5 Agustus 2018. Dia ditunjukkan bersama istrinya, Uldine.

Karen Warren/Houston Chronicle Tampilkan Lebih Banyak Tampilkan Lebih Sedikit

R.L. "Buddy" Frazier pensiun pada tahun 2009 sebagai kepala Departemen Kepolisian Katy setelah menjabat selama 13 tahun. Dia meninggal 1 Agustus 2018.

Katy Police Department / Katy Police Department Tampilkan Lebih Banyak Tampilkan Lebih Sedikit

Mantan Presiden George H.W. Ahli jantung Bush, Mark Hausknecht, ditembak mati saat mengendarai sepedanya ke tempat kerja 20 Juli 2018.

Penduduk lama Houston Anne Baker Cravens selamat dari serangan U-boat Jerman pada 3 September 1939. Dia meninggal 21 Juni 2018

Victoria Cheyne/Cary Cravens Doggett Tampilkan Lebih Banyak Tampilkan Lebih Sedikit

Diane Mosier, seorang advokat dan juara yang kuat untuk Partai Demokrat di Houston, meninggal pada 29 Juni 2018. Dia berusia 69 tahun.

Marie D. De Jesus/Houston Chronicle Tampilkan Lebih Banyak Tampilkan Lebih Sedikit

Selama lebih dari tiga dekade, Mildred McWhorter memberi makan, memberi pakaian, dan melayani ribuan orang Houston melalui misi Kristen yang dia bangun dari bawah ke atas. Dikenal sebagai “Miss Mac” oleh keluarga yang dia layani, dia meninggal pada 17 Juni 2018. Dia berusia 87 tahun.

Carlos Antonio Rios, staf HC / Houston Chronicle Tampilkan Lebih Banyak Tampilkan Lebih Sedikit

Petugas polisi Houston Norberto Ramon, dikenang sebagai pahlawan yang membantu menyelamatkan ratusan korban banjir selama Badai Harvey saat menjalani perawatan kanker, meninggal 15 Juni 2018.

Joe Scott Cathey, mantan wali ISD Taman Rusa yang mengabdi selama 25 tahun dan setelah itu hadir di acara atletik distrik, meninggal 14 Juni 2018. Dia berusia 88 tahun.

Petugas memberi hormat 21 tembakan selama Peringatan Petugas Polisi Houston pada 18 Mei 2018. Dari mantan ibu negara hingga pahlawan lokal, ini adalah beberapa area yang hilang dari penduduk Houston pada tahun 2018.

Michael Wyke / For the Chronicle Tampilkan Lebih Banyak Tampilkan Lebih Sedikit

Lenwood Johnson, yang tanpa henti melobi, mendesak, dan mengganggu pejabat pemerintah dalam upaya yang gagal untuk mencegah pembongkaran pembangunan perumahan umum terbesar di Houston, meninggal 11 Mei 2018. Dia berusia 75 tahun.

Johnny Hanson/Houston Chronicle Tampilkan Lebih Banyak Tampilkan Lebih Sedikit

Jermaine Robbins, ayah dari 11 anak dan sosok pelatih/ayah bagi ratusan atlet muda lainnya di Channelview, North Shore, dan Houston timur, meninggal 11 Mei 2018, dalam kecelakaan berperahu di Danau Conroe. Dia berusia 46 tahun.

Setelah menderita serangan jantung, Rapper Big T, Big T yang bernama asli Terence Prejean meninggal dunia pada 7 Mei 2018 dalam usia 52 tahun. Dijuluki "Million Dollar Hook Man", ia mengeluarkan beberapa album termasuk" Million Dollar Hooks" pada tahun 2001 dan "Power Move" pada tahun 2000.

Mantan ibu negara Barbara Bush meninggal 17 April 2018, pada usia 92 tahun karena komplikasi dari gagal jantung kongestif dan masalah pernapasan di rumahnya di Houston barat. Suaminya selama 73 tahun, George Herbert Walker Bush, berada di sisinya, memegang tangannya sepanjang hari.

David J. Phillip/Associated Press Tampilkan Lebih Banyak Tampilkan Lebih Sedikit

Pada tanggal 29 Maret 2018, slugger Mets tercinta yang masuk ke jurusan utama dengan Colt .45s/Astros, meninggal pada usia 73. Musim terbaik Staub dengan Astros termasuk 44 ganda dan penampilan All-Star.

Smiley N. Pool/Houston Chronicle Tampilkan Lebih Banyak Tampilkan Lebih Sedikit

George Oser, mantan anggota dewan sekolah ISD Houston yang berperan penting dalam proses desegregasi distrik pada 1970-an, meninggal 13 Maret 2018. Dia berusia 81 tahun.

Anggota Dewan Kota Houston Larry Green meninggal mendadak pada 6 Maret 2018, karena overdosis metamfetamin dan kloroetan, menurut pemeriksaan medis. Dia berusia 52 tahun.

Steve Gonzales / Houston Chronicle Tampilkan Lebih Banyak Tampilkan Lebih Sedikit

Legislator dan pengacara lama Jack 0gg, ditunjukkan ketika putrinya Kim Ogg meluncurkan pencalonan untuk jaksa wilayah Harris County, meninggal 3 Maret 2018. Dia berusia 84 tahun.

Mantan pemain sepak bola Rice Blain Padgett, 21, ditemukan tewas di dalam apartemennya di Houston pada 2 Maret 2018. Setelah rekan satu timnya menyadari dia melewatkan latihan pagi.

Hakim Paul Clarence Murphy III, salah satu dari dua hakim Partai Republik di Pengadilan Banding ke-14 yang memutuskan pada tahun 2000 bahwa undang-undang sodomi Texas yang berusia 100 tahun tidak konstitusional, meninggal pada 26 Februari 2018. Dia berusia 81 tahun.

Kolumnis gosip lama Houston, Betsy Parish, kanan, meninggal di gedung tinggi di daerah Tanglewood, 13 Februari 2018. Dia berusia 71 tahun.

Larry Reese, staf HC / Houston Chronicle Tampilkan Lebih Banyak Tampilkan Lebih Sedikit

Dr. John Mendelsohn, ilmuwan perintis dan arsitek di balik kemunculan MD Anderson Cancer Center sebagai rumah sakit kanker nomor 1 nasional, telah meninggal dunia. Dia berusia 82 tahun.

Mendelsohn menyerah pada glioblastoma, bentuk paling agresif dari kanker otak, Senin malam di rumahnya di Houston. Dia telah didiagnosis dengan penyakit 15 bulan yang lalu.

Mendelsohn menjabat sebagai presiden MD Anderson dari tahun 1996 hingga 2011, saat pertumbuhan terbesar institusi. Seorang ahli biologi molekuler, ia juga melakukan beberapa penelitian paling awal dalam terapi bertarget, jenis pengobatan yang lebih tepat mengidentifikasi dan menyerang sel kanker.

&ldquoMD Anderson memiliki keberuntungan besar yang dipimpin oleh John Mendelsohn selama 15 tahun dan langkah yang dibuat di bawah arahannya sangat luar biasa,&rdquo Dr. Peter Pisters, presiden MD Anderson, mengatakan dalam sebuah pernyataan.

&ldquoSelain prestasi yang mengesankan, baik sebagai ilmuwan maupun sebagai pemimpin, John adalah panutan dan inspirasi bagi banyak orang. Dia telah meninggalkan bekas yang tak terhapuskan di dunia ini, dan dia akan dikenang dan sangat dirindukan,&rdquo kata Pisters.

Mendiang mantan Presiden George H.W. Bush, teman lama dan pendukung MD Anderson yang berkonsultasi dengan Mendelsohn tentang beberapa masalah di Oval Office, tahun lalu menyebut Mendelsohn &ldquosalah satu gladiator terkemuka dalam perang melawan kanker &mdash inovatif, tak kenal lelah, tak kenal takut.&rdquo

Pertumbuhan pusat medis

Di bawah Mendelsohn, filantropi swasta MD Anderson meningkat hampir sepuluh kali lipat, anggarannya empat kali lipat, ruangnya tiga kali lipat dan jumlah karyawan dan pasiennya dua kali lipat. Itu juga mulai menerima lebih banyak hibah National Cancer Institute dan melakukan lebih banyak uji klinis untuk mengevaluasi perawatan kanker baru daripada institusi mana pun di dunia.

Selain itu, pusat kanker berkembang dari 28 gedung di Texas Medical Center menjadi 58 dan menjalin kemitraan dengan institusi di seluruh Amerika Serikat dan di Eropa, Timur Tengah, Asia, dan Amerika Selatan.

ESAI EVOCATIVE: Apa yang terjadi ketika seorang peneliti kanker terkena kanker? Hanya di HoustonChronicle.com.

Itu juga bergerak di depan Memorial Sloan-Kettering Cancer Center dalam survei rumah sakit tahunan US News and World Report. Setelah bertahun-tahun menempatkannya di No. 2, majalah itu menempatkan MD Anderson sebagai rumah sakit kanker teratas nasional ke delapan dari Mendelsohn dalam 10 tahun terakhir sebagai presiden, semuanya dari lima terakhir.

Penghormatan kepada Mendelsohn mengalir pada Selasa di kalangan kanker di seluruh negeri dan dari para pemimpin Texas dalam politik, akademisi, dan bisnis.

&ldquoMendelsohn adalah raksasa komunitas medis yang memperpanjang hidup banyak orang yang terancam oleh kanker, seorang pemimpin komunitas yang berusaha menjadikan Houston kota kelas dunia, dan manusia luar biasa yang menghabiskan seumur hidup untuk merawat orang lain,&rdquo mantan Menteri Luar Negeri James A. Baker III berkata.

Dan Perwakilan AS Sheila Jackson Lee, D-Houston, mengatakan Mendelsohn &ldquomembuat dampak abadi di dunia ini, membantu memimpin dan menginspirasi banyak orang di bawah komandonya. Terlahir sebagai pemimpin, pengaruhnya di bidang medis sangat mendalam.&rdquo

Dr. Paul Klotman, presiden Baylor College of Medicine, mengatakan kepemimpinan &ldquoMendelsohn&rsquos memiliki dampak yang jauh melampaui MD Anderson&rdquo dan Presiden Rice University David Leebron menyebutnya &ldquoa panutan bagi banyak dari kita di Houston.&rdquo

Mogul minyak legendaris T. Boone Pickens, yang memberi MD Anderson $50 juta pada tahun 2007, menyebut Mendelsohn lewat & ldquotough to take. Dia adalah seorang pembangun dan pemimpi yang membuat sesuatu terjadi. Saya bekerja erat dengannya selama bertahun-tahun dan menerima visinya secara besar-besaran. Yang saya inginkan hanyalah pembuat perbedaan, dan dia melakukannya dengan cepat.&rdquo

&lsquoPerawatan pasien yang baik&rsquo

Mendelsohn pensiun dari MD Anderson pada musim panas 2018, di tengah pertempuran kanker. Dia menjabat sebagai co-director dari rumah sakit penelitian Houston Institute for Personalized Cancer Therapy tujuh tahun sebelumnya, setelah mengundurkan diri dari kepresidenan pada usia 75. Setelah pensiun, dia diangkat sebagai presiden emeritus, yang pertama di MD Anderson.

Dijuluki &ldquoCentral Casting&rdquo oleh beberapa fakultas karena dia begitu terlihat berperan, Mendelsohn hanyalah presiden ketiga dalam sejarah MD Anderson. Dia juga merupakan komoditas langka di antara presiden di Texas Medical Center pada saat itu &mdash orang luar.

Dia tetap &ldquoa sempurna,&rdquo menurut James Olson, penulis &ldquoMaking Cancer History: Disease and Discovery di University of Texas M.D. Anderson Cancer Center&rdquo dan sejarawan Sam Houston State University.

&ldquoDia memiliki kebijaksanaan untuk mempertahankan reputasi MD Anderson untuk perawatan pasien yang baik,&rdquo kata Olson. &ldquoDia adalah ilmuwan terkemuka di garis depan penelitian baru mutakhir yang memposisikan M.D. Anderson sebagai pemimpin di arena. Dan dia memiliki kepribadian dan wajah untuk bekerja secara luar biasa dengan para pemimpin politik dan keuangan komunitas.&rdquo

Mendelsohn datang ke MD Anderson pada saat yang penuh tantangan. Sebuah laporan konsultan baru saja menyarankan pusat untuk mengencangkan ikat pinggang dan menutup departemen, tanggapan yang tampaknya logis untuk perusahaan asuransi kemudian praktik baru mengarahkan pasien ke rumah sakit komunitas berbiaya lebih rendah. Itu digambarkan pada saat itu sebagai &ldquoa gambar malapetaka-dan-kesuraman.&rdquo

Sebaliknya, Mendelsohn&rsquos mengabaikan saran dan MD Anderson berkembang, tumbuh menjadi kerajaan virtual dan mendominasi bidang perawatan kanker.

Kehidupan awal dan penelitian

Mendelsohn lahir di Cincinnati pada 31 Agustus 1936, putra seorang ibu rumah tangga dan penjual suspender dan ikat pinggang pria. Ia memperoleh gelar sarjana dan kedokteran dari Universitas Harvard, kemudian menghabiskan satu tahun di Skotlandia di Universitas Glasgow sebagai Fulbright Scholar dalam bidang biokimia.

Dia awalnya berniat untuk belajar kedokteran. Tidak yakin tentang jalur karirnya, ia awalnya mengambil jurusan fisika dan kimia sebagai sarjana Harvard College sebelum menetap di biokimia.

Sebagai seorang sarjana, Mendelsohn bekerja di lab James Watson, seorang ahli biologi berusia 28 tahun yang kemudian memenangkan Hadiah Nobel untuk penemuan bersama struktur heliks ganda DNA beberapa tahun kemudian. Mendelsohn adalah sarjana pertama yang pernah bekerja di lab Watson.

Olson menyebut karir Mendelsohn&rsquos &ldquoits sendiri heliks ganda, serangkaian prestasi medis dan ilmiah melingkar erat dengan evolusi pengobatan kanker di abad kedua puluh.&rdquo

Setelah sekolah kedokteran, Mendelsohn berlatih penyakit dalam di Brigham and Women's Hospital di Boston dan menghabiskan dua tahun sebagai peneliti di National Institutes of Health sebelum menyelesaikan fellowship hematologi-onkologi di Washington University Medical School di St. Louis.

Dia kemudian bergabung dengan University of California di San Diego School of Medicine, pertama sebagai asisten profesor, akhirnya diangkat sebagai direktur pendiri pusat kankernya. Penelitiannya di sana mengarah pada pengembangan antibodi monoklonal cetuximab (Erbitux), obat target pertama, yang kemudian menerima persetujuan Food and Drug Administration untuk kanker kolorektal stadium lanjut pada tahun 2004 dan untuk kanker kepala dan leher pada tahun 2006.

Pada tahun 1985, Mendelsohn meninggalkan San Diego untuk menjadi ketua Departemen Kedokteran di Pusat Kanker Memorial Sloan Kettering di New York, yang kemudian menjadi pusat kanker peringkat teratas nasional. Di sana, kata Olson, dia memimpin pemberontakan melawan "prosedur super-radikal dari ahli bedah seperti George Pack dan Jerome A. Urban yang mendukung operasi yang lebih konservatif yang dikombinasikan dengan terapi radiasi dan kemoterapi, yang mempertahankan tingkat kelangsungan hidup yang ada sambil meninggalkan pasien dengan lebih sedikit sisi. efek.&rdquo

Sebelas tahun kemudian, yang membuat takjub beberapa rekannya, dia lari ke MD Anderson.

&ldquoDimulai dengan ketukan saya di pintu laboratorium Watson, saya mengambil kesempatan ketika mereka muncul,&rdquo Mendelsohn pernah berkata.

&lsquoMembuat sejarah kanker&rsquo

Selama masa Mendelsohn&rsquos, tema &ldquoMD Anderson: Making Cancer History&rdquo berasal dan menjadi merek dagang. Pusat kanker juga menjadi universitas pemberi gelar, menganugerahkan gelar sarjana dan master dalam ilmu biomedis serta gelar sarjana dan master dalam berbagai disiplin ilmu kesehatan yang terkait.

Ia juga mengutamakan kepuasan pasien. Dia menyederhanakan sistem telepon sehingga penelepon dapat menghubungi orang langsung setelah menekan satu tombol. Dia mempekerjakan lebih banyak ahli radiologi dan patologi untuk mempersingkat waktu menunggu hasil tes dan dia menetapkan kebijakan untuk membawa pasien ke dokter dalam waktu empat hari setelah membuat janji.

&ldquoDia adalah seorang visioner, seorang optimis tanpa henti yang selalu melihat kemungkinan,&rdquo kata Margaret Kripke, kepala akademik di bawah Mendelsohn dan mantan anggota President Cancer Panel, panel tiga orang yang memberikan saran kebijakan kepada Gedung Putih. &ldquoDia hebat dalam mendapatkan penelitian dari lab dan masuk ke klinik, melayani kepentingan pasien, bukan hanya sains&rsquo.

Kepresidenannya bukan tanpa hambatan. Pada tahun 2002, Mendelsohn menemukan dirinya terlibat dalam kontroversi karena perannya dengan dua perusahaan bermasalah: Enron, yang tipu muslihat akuntansi dan penipuan akhirnya menyebabkan kebangkrutan yang merugikan investor miliaran dan waktu penjara untuk CEO dan ImClone Systems, sebuah perusahaan bioteknologi yang CEO mengaku bersalah. untuk perdagangan orang dalam atas obat Mendelsohn&rsquos Erbitux. Mendelsohn bertugas di dewan ImClone dan Enron, termasuk komite audit yang terakhir.

Mendelsohn tidak pernah dikaitkan dengan perdagangan orang dalam Imclone, meskipun dia tersentuh oleh kontroversi lain dengan perusahaan ketika terungkap bahwa dari 1997 hingga 2001, MD Anderson menguji Erbitux pada pasien tanpa memberi tahu mereka bahwa dia memiliki kepentingan finansial di dalamnya.

Mendelsohn terpilih ke beberapa organisasi paling bergengsi di negara itu, termasuk Divisi Kesehatan dan Kedokteran dari Akademi Ilmu Pengetahuan Nasional dan Akademi Seni dan Ilmu Pengetahuan. Penghargaan termasuk Medali Prestasi Seumur Hidup Fulbright 2005 untuk kontribusi yang telah &ldquomemperluas batas kebijaksanaan manusia&rdquo Medali Kehormatan American Cancer Society untuk Penelitian Klinis, American Society of Clinical Oncology&rsquos Distinguished Achievement Award dan Penghargaan Tang yang bergengsi dalam Ilmu Biofarmasi.

Selama 10 tahun, ia menjabat sebagai editor pendiri Clinical Cancer Research, sebuah jurnal American Association for Cancer Research yang berfokus pada penelitian translasi yang dapat menerapkan terapi bertarget molekuler lebih cepat kepada pasien kanker.

Mendelsohn meninggalkan seorang istri, putra Anne Andrew, Eric dan Jeff dan delapan cucu.

Sebuah upacara peringatan akan diadakan Senin pukul 11 ​​pagi di Teater Cullen di Wortham Center.

Mengingat Dr. John Mendelsohn

James A. Baker III, mantan Menteri Luar Negeri AS
"John Mendelsohn adalah seorang raksasa komunitas medis yang memperpanjang hidup banyak orang yang terancam oleh kanker, seorang pemimpin komunitas yang berusaha menjadikan Houston kota kelas dunia, dan manusia luar biasa yang menghabiskan seumur hidup untuk merawat orang lain," kata James A. Baker, III, Menteri Luar Negeri AS ke-61 dan anggota Dewan Pengunjung MD Anderson sejak 1974. "Kita semua akan merindukan pikirannya yang cemerlang, kepribadiannya yang bijaksana, dan dedikasinya kepada dunia yang mengelilinginya. Istri saya, Susan, dan saya mengirim John's istri, Anne, dan seluruh keluarga mereka, simpati kami yang terdalam."

Sheila Jackson Lee, Anggota Kongres AS
"Dari Harvard hingga Fulbright dan ke dalam dunia penelitian dan kedokteran, Dr. Mendelsohn membuat dampak yang bertahan lama di dunia ini, membantu memimpin dan menginspirasi banyak orang di bawah komandonya. Seorang pemimpin yang terlahir, pengaruhnya di bidang medis sangat besar dan dia akan sangat diingat dan sangat dirindukan."

David Leebron, presiden Universitas Rice
"Houston telah kehilangan seorang pemimpin yang luar biasa dengan meninggalnya John Mendelsohn, yang 15 tahun kepemimpinannya menjadikan MD Anderson Cancer Center yang terbaik di dunia. Dia adalah panutan bagi banyak dari kita di Houston dan saya akan sangat merindukan kebijaksanaannya. dan optimisme tanpa henti."

Dr. Paul Klotman, presiden Fakultas Kedokteran Baylor
"Kepemimpinan Dr. John Mendelsohn memiliki dampak yang jauh melampaui MD Anderson Cancer Center. Komitmennya terhadap Texas Medical Center dan pertumbuhannya telah melayani semua institusi. Kontribusinya pada sains dan khususnya bidang penelitian kanker sangat signifikan. Dia akan dirindukan. "

James Milliken, rektor Universitas Sistem Texas
Sistem UT berduka atas meninggalnya John Mendelsohn, presiden emeritus MD Anderson dan seorang kemanusiaan besar yang menetapkan standar emas untuk perawatan kanker, kasih sayang, kepemimpinan dan kebaikan. Gaya dan kecemerlangannya menginspirasi semua orang yang bekerja dengannya untuk menjadi yang terbaik. Penerima manfaatnya termasuk pasien dan keluarga dari seluruh dunia, yang hidupnya menjadi lebih baik tidak hanya dengan penemuan dan perawatannya, tetapi juga oleh martabat dan ketulusan yang dia gunakan untuk memperlakukan semua orang."

T. Boone Pickens, maestro minyak
"Meninggalnya John Mendelsohn sangat sulit untuk diterima. Dia adalah seorang pembangun dan pemimpi yang membuat banyak hal terjadi. Semangatnya untuk menyembuhkan kanker dalam segala bentuk membantu mengubah komunitas medis di Houston, Texas dan bangsa dan, dengan melakukan itu, membangun MD Anderson sebagai institusi kanker terkemuka di dunia. Saya bekerja erat dengannya selama bertahun-tahun dan membeli visinya secara besar-besaran. Yang saya inginkan hanyalah pembuat perbedaan, dan dia menyampaikannya dengan cepat. Pikiran dan doa bersama keluarganya saat kita berhenti bersama untuk memperingati warisan abadinya. Suatu hari kita akan berhasil membersihkan dunia dari kanker dan melihat John sebagai pelopor sejati dalam perjuangan ini."

BERITA KETIKA ANDA MEMBUTUHKANNYA: Teks CHRON ke 77453 untuk menerima peringatan berita terbaru melalui pesan teks | Daftar untuk mendapatkan pemberitahuan berita terbaru dikirim ke email Anda di sini.


Dua pria tunggal berbagi kehebatan yang luar biasa: Waun Ki Hong dan John Mendelsohn

Waun Ki Hong dan John Mendelsohn adalah kekuatan tunggal yang bergabung untuk mengubah dunia onkologi dan, dalam prosesnya, kehidupan peserta pelatihan, fakultas, pasien, dan keluarga yang tak terhitung jumlahnya.

Setelah raksasa penelitian dan pengobatan kanker ini meninggal bulan lalu&mdashmereka meninggal dalam selang waktu lima hari&mdashbanyak yang dikatakan tentang karir dan penghargaan mereka, yang ada banyak. Semua ini penting, tetapi sudah selesai, dan sekarang kita dapat melihat beberapa unsur kepemimpinan yang tak lekang oleh waktu dan naluriah yang membentuk kesuksesan Ki’s dan John’s.

Melalui banyak interaksi, pendekatan mereka terhadap kehidupan saling bersinergi, dan mereka benar-benar menjadi legenda yang mereka ciptakan. Hubungan itu tidak dangkal. Mereka setara, dan mereka meluangkan waktu untuk belajar dari satu sama lain. Mereka bekerja dan bermain (tenis) bersama, mereka mendiskusikan program dan sains, dan pada akhirnya, mereka saling menjaga. Apakah mereka secara eksplisit membahas prinsip-prinsip kepemimpinan, kita mungkin tidak pernah tahu, tetapi kedekatan hubungan menunjukkan bahwa mereka berkomunikasi secara mendalam tentang bagaimana bekerja secara efektif dalam konteks sistem akademik dan ilmiah yang kompleks untuk mencapai tujuan pribadi mereka sambil mempromosikan tujuan institusional dan pekerjaan serta karier. dari yang lain.

Kami yang cukup beruntung telah menjadi mentee dan rekan-rekan Ki dan John mengalami dinamika dan pengaruh unik masing-masing. Apa mereka melakukannya, dan dampaknya, adalah masalah catatan publik bagaimana mereka melakukannya adalah masalah lain sama sekali.

Selama sebulan terakhir, kami telah merenungkan secara mendalam sejarah dan pengalaman kami dengan Ki dan John, dan menemukan diri kami meneliti aspek-aspek yang tidak banyak diketahui dari karir mereka, memperoleh wawasan dengan melacak siswa dan kolega yang senang untuk mengenang dan mengingat sangat terukir, sayang kenangan orang-orang ini, mencapai sejauh awal 1970-an.

Kami dikejutkan oleh bagaimana pendekatan, sikap dan pandangan, keputusan dan watak Ki' dan John membuat mereka menjadi pemimpin. Meskipun banyak yang ditulis tentang ilmu kepemimpinan, Ki dan John, melalui pencapaian individu dan bersama mereka, dapat menulis sebuah buku bagus tentang seni kepemimpinan terapan, beberapa di antaranya disajikan di bawah ini.

Sementara teknologi dan metodologi ilmiah berubah secara dramatis selama karir Ki's dan John's, bahan kepemimpinan telah bertahan dalam ujian waktu&

Anda tidak pernah tahu kapan pertemuan rutin atau kebetulan bisa menjadi momen yang menentukan karier.

Kedua pria itu memanfaatkan peluang yang tampaknya kecil itu sebaik-baiknya ketika mereka menampilkan diri mereka sendiri dan menciptakan jeda&mdash mereka sendiri seperti ketika seorang sarjana Harvard (John) mengetuk pintu asisten profesor baru bernama James Watson. Ketahuilah bahwa setiap pertemuan dapat meninggalkan kesan abadi. Kembangkan &ldquopresence,&rdquo dan persiapan, untuk membuat interaksi kecil menjadi penting.

Bagi Ki, itu adalah wawancara persekutuan tahun 1973 di Sloan Kettering, di mana Irwin Krakoff, yang saat itu menjabat sebagai kepala Layanan Onkologi Medis, dapat membedakan melalui bahasa Inggris yang sulit semangat, wawasan, dan fokus yang kuat yang menjadi ciri awal karir Ki’s. Penasaran, Krakoff mengawasi Ki selama persekutuannya dan awal karir fakultasnya di Boston Veterans Affairs dengan mencatat rekam jejak Ki’ yang luar biasa dalam menghadirkan presisi dan ketajaman untuk uji klinis yang menantang.

Krakoff juga terkesan dengan kemampuan Ki's untuk bekerja (dia sering berkata, &ldquoSaya hanya menganggap diri saya memiliki kecerdasan rata-rata, tetapi saya dapat bekerja lebih baik dari kebanyakan orang&rdquo) menyerap semua yang dia bisa pelajari selama persekutuan dari orang-orang seperti Joseph Burchenal, David Karnofsky, dan Robert Wittes, saat dia menghadapi masalah klinis yang sangat sulit. Karir fakultas awal Ki's di Boston VA, berfokus pada kanker kepala dan leher, mengembangkan serangkaian uji klinis yang saling terkait dan inovatif yang dirancang untuk menghentikan proses penyakit ini, mulai dari kemoterapi neoadjuvant hingga kemoprevensi, masing-masing di ujung tombak penelitian translasi.

Krakoff direkrut ke MD Anderson pada tahun 1983 untuk meningkatkan status akademik Divisi Kedokteran setahun kemudian (dan 10 tahun setelah wawancara persekutuan yang mengesankan), Ki direkrut untuk membawa ketelitian ke program uji klinis sebagai kepala Bagian Kepala dan Onkologi Medis Leher, kemudian Charles A. LeMaistre Ketua Departemen Onkologi Medis Toraks/Kepala dan Leher di MD Anderson. Pada catatan terkait, kesan abadi selama persekutuannya mengarahkan Wittes, yang telah pindah ke Program Evaluasi Terapi Kanker NCI, untuk menghubungkannya beberapa tahun kemudian dengan ahli bedah Greg Wolf, yang memimpin Program Kontrak Kepala dan Leher NCI HNCP-178, yang menetapkan panggung bagi pasangan untuk merancang dan memimpin uji coba pelestarian kanker laring VACSP-268 yang penting.

Bagi John, itu selama residensinya di Brigham and Women's Hospital. Pertemuan kebetulan dengan profesor tamu dari NIH, Eugene Braunwald, akan menjadi momen yang menentukan dalam karirnya.

Braunwald menyadari sejak awal bahwa John memiliki &ldquohadiah&rdquo kepemimpinan yang melekat: dorongan, visi, karisma. Beberapa tahun kemudian, saat menyelesaikan beasiswa hematologi-onkologi di Universitas Washington, John menerima telepon dari Braunwald, yang telah pindah ke Universitas California San Diego (UCSD) pada tahun 1968 sebagai ketua pendiri Departemen Kedokteran, di mana dia ingin untuk membangun kehadiran yang kuat dalam onkologi.

Dia memikirkan John, memperkenalkannya kepada kepala divisi hematologi Mickey Goulian, yang segera mengenali bakat dan kemampuan John. Mereka merekrut John ke UCSD pada tahun 1970, membujuknya untuk keluar dari akar Liga Ivy yang sudah mapan dengan kesempatan untuk benar-benar &ldquomembangun onkologi dari bawah ke atas&rdquo di universitas berusia 2 tahun yang menarik dan bersemangat ini.

Menjalin hubungan dengan rekan kerja dan pesaing untuk membangun rasa saling menghormati dan memajukan lapangan.

Ki dan John ahli dalam meyakinkan dan memotivasi orang untuk bergabung dan berkolaborasi dengan mereka, menggunakan banyak strategi yang dikenal untuk membangun hubungan. John membentuk dan mengubah tiga pusat kanker utama sambil meluncurkan dan mendorong era terapi bertarget.

Namun, kami menyoroti pendekatan Ki terhadap prinsip ini karena keunikannya sebagai taktik dalam kedokteran akademis. Meskipun kami ragu Ki pernah membaca buku kepemimpinan, dia jelas memahami teknik yang terkandung dalam kejeniusan Abraham Lincoln, seperti yang digariskan dalam Tim Saingan oleh Doris Kearns Goodwin.

Ki memiliki kemampuan bawaan untuk membina hubungan dengan rekan kerja dan pesaing dengan secara bersamaan bersaing dan mempromosikan kepentingan individu-individu ini. Dengan intuisi politik yang dalam, Ki membangun tim yang terdiri dari teman, kolega, dan bahkan saingan tepercaya untuk memajukan penelitian dan perawatan kanker .

Dia menemukan cara untuk memungkinkan setiap pesaingnya&mdashtermasuk pencela&mdashuntuk berkontribusi pada pengobatan kanker, di mana mereka dapat mencapai kesuksesan pribadi, dengan demikian memajukan bidang dan, disengaja atau tidak, secara bersamaan meningkatkan status Ki’s. Sepanjang karirnya, Ki mencurahkan banyak waktu dan upaya untuk meningkatkan karir orang lain&mdashnominasi dan dengan penuh semangat mengadvokasi rekan kerja dan pesaing sama-sama untuk penghargaan dan penghargaan besar.

Taktik ini sekaligus merupakan tindakan tanpa pamrih, namun juga merupakan salah satu dengan pengembalian investasi yang besar, menghasilkan rasa saling menghormati dan kekaguman yang sudah berlangsung lama. Keberhasilan strategi ini diulang sepanjang karirnya, dan dengan setiap keberhasilan menjadi aspek penguatan diri dari interaksi Ki's yang sangat efektif dengan orang lain. Ini adalah seorang jenius politik yang setara dengan Lincoln.

Berpikir luas, melihat ke depan, mengenali dan mempromosikan bakat.

John direkrut ke UCSD untuk membangun program onkologi, tetapi keahliannya adalah sebagai dokter-ilmuwan hematologi dengan pelatihan fellowship tambahan di NIH, memimpin upaya laboratorium dasar yang besar.

Dia tahu dia perlu membawa pemimpin nasional dalam uji klinis tumor padat, jadi pada tahun 1976, tahun John menjadi Direktur Pusat Kanker UCSD pendiri, dia merekrut mendiang Mark Green, salah satu ahli onkologi paling dihormati di Amerika Serikat, terkenal untuk pengetahuan ensiklopedisnya tentang onkologi klinis (dan menghafal nomor rekam medis pasiennya.)

John selalu mencari cara untuk memperluas cakupan dan kedalaman Pusat Kanker UCSD dengan anggarannya yang sederhana. Dia berhasil mempromosikan dan memanfaatkan kemitraan akademik dan akademik-industri, dan dengan penuh semangat melibatkan para pemimpin masyarakat.

His broad vision is illustrated by his early years at UCSD, building the cancer program and center to encompass very basic studies of T-cell receptor biology, advancing disruptive monoclonal technology and establishing a nascent effort in community engagement.

In 1981, John recruited Georgia Sadler to be the associate director for administration, also realizing that her doctoral training in public health would be a real asset in helping him to expand the breadth of the center.

He supported her efforts to create public education and awareness programs highlighting the importance of cancer prevention and clinical trial participation. This outreach effort had a strong regional focus on reducing cancer disparities, placing meaningful value on what we now call &ldquocatchment area,&rdquo making John one of the nation’s first directors of an NCI-designated cancer center to use community-campus partnerships as an effective cancer control strategy.

Embrace difficult challenges that address simple, compelling, and worthy questions.

Ki and John developed groundbreaking, yet straightforward, simple and compelling research hypotheses that addressed meaningful problems.

While simple in retrospect, each breakthrough was incredibly difficult and challenging to operationalize and implement, requiring tenacity, resilience and creativity in the face of opposition and scientific concerns regarding the validity of their research ideas and feasibility.

For example, though the idea behind Ki’s Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) study was simple and compelling&mdashbase targeted drug selection on saat ini tumor biology&mdashit was unprecedented and prompted vigorous debate, skepticism, and even ethical resistance.

The controversy centered on the risk of the core needle re-biopsy required to base drug selection on current biology in the second line setting, versus the risk of inaccurately selecting drug therapy or pathway targets from archival diagnostic tissue.

Despite the skepticism, BATTLE established the feasibility of a challenging precision therapy protocol design that has become an established approach in cancer medicine.

Related to his principle of simple, straightforward hypotheses, Ki designed trials to answer important questions, contributing valuable information, regardless of the result&mdashthis was his &ldquono lose approach&rdquo to cancer research .

In 1980, John’s groundbreaking hypothesis that launched the era of targeted therapy was, at its core, quite simple&mdashmake an antibody to prevent the growth factor-receptor connection, in this case epidermal growth factor receptor (EGFR) to block cell proliferation.

The hypothesis, however, was based on circumstantial evidence, including basic studies of transferrin- and acetylcholine-receptor biology, but no direct experimental data. In fact, prevailing data revealed that monoclonal antibodies functioned as agonists in this setting. Unprecedented, uncertain, and unfunded, John partnered with Gordon Sato, to push the idea to reality through initially scraping together funds for preliminary hybridoma studies, screening thousands of antibodies over several years to find a lead compound (225) with strong antagonist, blocking activity. John moved to Sloan Kettering in 1985, continuing his 225 work, and led seminal studies driving the development of 4D5 and Herceptin with Rakesh Kumar and José Baselga.

These are but a few examples of the approach to leadership embodied and employed by these two great men. There were many similarly important principles in other aspects of their careers, including seamlessly integrating education and training into the fabric of cancer research and care: creatively designed and funded innovative and transformational training mechanisms such as an advanced scholars program.

Having the incredible fortune to work with them over many years, as well as listening to the stories told by former students and colleagues, was exciting and compelling. Ki and John didn’t write an actual book about their leadership experiences, but they &ldquowrote the book,&rdquo figuratively, and that bears noting&mdashand retelling.

Read more: For a more in-depth look at the lives of these two extraordinary and inspirational individuals, please read our tribute in Cancer Cell , publishing on Feb. 11, 2019. (The link will go live on the day of publication.)


Mendelson Collection

Scope: A personal collection of printed books and journals in German and French of the 20th century mainly on politics, economics, history, literature and the fine arts, assembled by John Jakob Mendelson, M.P.

Tanggal: 1908-1977 (a few earlier items)
Extent: C. 3000 vols.
Name of creator: John Jakob Mendelson

Administrative / biographical history:

The collection is a part of the personal library of John Mendelson, Labour M.P for Penistone 1959-1978. On his death in 1978 his library was bequeathed to the Northern College, a residential adult education college at Wentworth Castle, near Barnsley, which later arranged for the French- and German-language material to be placed in the University of Sheffield Library on permanent loan. Although covering a wide range of subjects and countries, the collection relates principally to politics, economics, history, literature and the fine arts, and is particularly rich in material on German and French political and economic history, especially of the twentieth century, including works on the rise of fascism, communism and socialism, and post-war conditions in Europe after 1945. German language material predominates, accounting for approximately three-quarters, and French one quarter, of the collection, and runs of several German language serials are represented. John Mendelson spoke German and French fluently, and this interest is reflected in the composition of his personal book collection.

John Jakob Mendelson (1917-1978), an intellectual on the left of the Labour Party, was born of Polish parents and educated in France, and at the University of London where he took the degree of BSc Econ. He gained experience of industrial affairs by working in factories in the North of England. Service in the Army during World War II brought him the rank of Captain. His connection with Sheffield and its University was close: in 1949 he was appointed Lecturer in Economics and Public Administration in the Department of Extramural Studies, a post which he held until entering Parliament at a by-election in 1959, and he served as Vice-President of the Sheffield Trades and Labour Council. In the Commons he became politically a force on the Left, firstly in the Bevan group and later in the Tribune group of MPs, though his independent viewpoint on various issues led to clashes with other members.

During the debate on German rearmament in 1959 Mendelson joined with Richard Crossman in tabliing a Commons motion condemning any possible proposal to provide West Germany with atomic weapons, and he was a leading critic of American involvement in Vietnam, travelling to the United States to discuss American policy with members of the US Government. But after the February 1974 General Election, when many younger and more extreme MPs joined the Tribune Group, his name was omitted from the list of contenders for places on the National Executive Committee of the Labour Party.

[Notes based on the Waktu obituary 22 May 1978 and entry in Whos Who]


--> Mendelsohn, John, 1936-

John Mendelsohn, M.D. is the third person who has served as president of The University of Texas MD Anderson Cancer Center. Under his leadership and direction, the institution has emerged as the nation’s premier cancer center. It has more than doubled in size and has been named the top cancer hospital in the nation seven out of the past nine years in U.S. News and World Report's "America's Best Hospitals" survey, including 2010.

Born in Cincinnati, Ohio on August 31, 1936, Mendelsohn earned both bachelor’s and medical degrees from Harvard University and spent a year in Scotland at the University of Glasgow as a Fulbright Scholar in biochemistry. Following his residency training in internal medicine at Brigham and Women’s Hospital in Boston, he completed a research fellowship at the National Institutes of Health and completed a fellowship in hematology-oncology at Washington University Medical School.

In 1970, he joined the faculty at the University of California, San Diego, becoming founding director of the National Cancer Institute-designated cancer center there. In 1985, Mendelsohn moved to New York where he chaired the Department of Medicine at Memorial Sloan Kettering Cancer Center for 11 years. In addition he held the Winthrop Rockefeller Chair in Medical Oncology, served as co-head of the Program in Molecular Pharmacology and Therapeutics, and served as professor and vice chairman of medicine at Cornell University Medical College. Mendelsohn accepted the appointment of president at The University of Texas MD Anderson Cancer Center in 1996.

Dr. Mendelsohn has received multiple honors and awards for his contributions and advancements in cancer research and patient care. Past honors include the David A. Karnofsky Memorial Award from the American Society of Clinical Oncology (2002), the Fulbright Lifetime Achievement Medal (2005), the Dan David Prize in Cancer Therapy (2006), and the Dorothy P. Landon-AACR Prize for Translational Research (2008). He has been on numerous editorial boards as well as serving for ten years as the founding editor-in-chief of Clinical Cancer Research. Mendelsohn has also authored more than 250 scientific papers and articles for journals and books.

After guiding and directing MD Anderson during many years of remarkable growth and expansion, Dr. Mendelsohn announced on December 6, 2010 his plans to relinquish his position as president until a new successor is appointed. He will continue to have an active role in carrying out the institution’s mission by remaining on the faculty as co-director of the new Institute for Personalized Cancer Therapy.

From the guide to the John Mendelsohn, M. D. Oral History Interview 1 Mendelsohn_John_20050103., January 3, 2005, (Historical Resources Center, Research Medical Library, The University of Texas M. D. Anderson Cancer Center)


Abstrak

Waun Ki Hong and John Mendelsohn were vastly different characters, with different backgrounds and strengths. Yet once together at The University of Texas MD Anderson Cancer Center in Houston, the combination of these 2 great men had an enormous impact on reinvigorating the institution and generations of physicians, scientists, and patients.

Waun Ki Hong and John Mendelsohn died within 5 days of one another in early January 2019. Both were good men and remarkably effective leaders whose individual and shared impact on The University of Texas MD Anderson Cancer Center (MDACC) in Houston would prove immense. Both were well-funded and much-admired scholars and mentors, gentlemen in the best sense of the word, and leading physician scientists. Over the course of almost 2 decades, from 1996 until 2014, these 2 remarkable but different men, already friendly when Dr. Mendelsohn joined MDACC 12 years after Dr. Hong, would become staunch allies, tennis partners, and most important, fundamental leaders and co-conspirators in the repurposing and rebranding of MDACC as the world's largest, best-funded, and most famous translational cancer center. However, the alliance that sparked between these 2 determined individuals, and which now may appear to have been predestined, was not always the sure thing that people today assume it was. And although we were fortunate enough to see it launch, others were closer to its continuation and seemingly relentless success in later years. Some conditions were unique to the 2 men and to that singular institution. But the lessons in institution building are worth considering, even while appreciating the enduring legacies of these 2 singular individuals (Figs. 1 and 2).

First, both Waun Ki Hong and John Mendelsohn were shrewd and careful identifiers and mentors of gifted and dedicated individuals, even to the point that they could repurpose human talent, getting the most from individuals. Both men enabled the successes of their team members, carefully mentored or co-mentored, held folks accountable, and ultimately reveled in the many successes of their mentees. They were always looking for the next great star, while simultaneously ensuring they protected the self-esteem of their current proteges. Both were also excellent observers of human nature, Dr. Hong in particular, in terms of reducing the pressure on folks when it was clear that an individual or a team needed time to recharge their batteries. This occurred at both the physician/scientist level and at that of the entire staff.

What was the state of the MDACC that Waun Ki Hong found in 1984, and the one that John Mendelsohn arrived at in 1996? Dr. Hong arrived at an institution where clinical care and clinical investigation focusing on the cure of cancer were the coins of the realm. Based on the development of basic biologic research in cancer as well as the development of new compounds, combination therapy, and technologic innovation, the center was already thriving under the aegis of the remarkable Emil J. Freireich (and his close friend and colleague Emil Frei before him, who left for the Dana-Farber Cancer Institute in Boston), one of the major modern pioneers of anticancer chemotherapy. High-dose therapy and bone marrow transplantation were emerging as forces for cure in hematologic malignancies and soon would be widely tested in solid tumors as well. Dr. Hong was already a pioneer in induction chemotherapy when he arrived in Houston, but he brought to MDACC the entirely new dimension of cancer chemoprevention, a field in which he pioneered building teams to conduct large studies in former smokers with a focus on cancers of the lung and head and neck. When John Mendelsohn arrived at MDACC in 1996, the institution was thriving from the perspective of clinical volume and arguably was the top institution for cancer clinical trials involving chemotherapy, novel radiotherapy, surgical approaches, and biologics. However, Dr. Mendelsohn, coming from Memorial Sloan Kettering Cancer Center in New York City, brought the rigor of a scientist who had developed an entirely new class of compounds, the antibodies to the epidermal growth factor receptor (EGFR). And he was looking for a different type of clinical investigator, one who could discern clues from changes in the tissues and blood levels of the target, something Dr. Hong had been collaborating with Reuben Lotan to define in the retinoid chemoprevention field. So the science, the drive, the mutual interest in defining a new, more translational, more visible, and more marketable cancer center had found its perfect combination.

The 2 men could simply have built on the strengths of MDACC, rather than remold it in the long run into an institution that is perpetually growing, leading, launching local and international strategic alliances, and becoming the most far-reaching cancer center in the world. But more of the same was not a prerogative for either man, and so together they endeavored to move the center in a new, specific direction based on a shared vision. They took that fork in the road, and MDACC will forever be transformed by their friendship and their alliance. They cast their nets widely, working with industry, the US government, the National Cancer Institute, and philanthropy, but always with their ultimate focus on advancing the cause of the patient with cancer.

From the beginning, the 2 men were clearly at ease together. They played tennis regularly, co-recruited a different breed of young investigator, and were constantly targeting a different type of senior scientist to fit their shared agenda. They both were completely focused on the patient, bringing new therapies from the laboratory to the clinic. Dr. Mendelsohn, in particular, dramatically increased the visibility of the MDACC, not only in Houston and in Texas, but in the United States and internationally, both among lay people and people of influence. Meanwhile, Dr. Hong built powerful and enduring scientific and clinical alliances with other top scholars, both within MDACC and from top academic institutions the world over. Each of the 2 had his towering strengths, and the ease with which they would move into position to allow one another to shine was evident from their early days together in Houston, and at both national and international meetings. They were natural allies who understood their goals and synchronized their agendas and their assets to get the job done.

From this perspective, Dr. Hong emerges as arguably one of the single best builders of teams and individuals we have seen in hematology, oncology, or cancer medicine. His myriad sports analogies (mostly football and baseball based, with a few basketball analogies thrown in) emphasized effort, commitment, the willingness to sacrifice for the team, and the need to close the deal when within striking distance. A particular favorite was his exhortation: “Don't fumble. Grip the ball and try to hammer it in from the 2-yard line. Put the points on the scoreboard—kick a field goal if you can't get a touchdown.” It was Hong-speak for calm down, do the careful final work methodically, don't get nervous or boast, and publish the high-impact article (or secure the high-value grant) carefully, scientifically, methodically. Gather a team of like-minded, determined, unselfish but equally ambitious folks and go for it.

This was an area in which Dr. Hong had few if any equals. He recruited members and built large, successful, cohesive teams, one individual at a time. He made a habit of allowing people to thrive and never allowing them to get too low, but also pushed them neither to bask too long in their successes nor to dwell in their failures. He preferred the team win and loved to apportion credit across the team and to all its members.

That was Dr. Hong's special magic. One on one, or one on few, he was masterful, and we have rarely ever seen his equal as a mentor. From that perspective, Dr. Mendelsohn, visionary and inspiring in public but not nearly as hands on with so many in private, brought an entirely different, complementary skill set. He was not Dr. Hong's equal as a builder of confident, assured clinical investigators he was a laboratory-based scientist, one who took the story of EGFR and developed antibodies, identified the clinical situation, and then focused on bringing this new targeted therapy to the clinic, presaging the field of targeted therapies. Both were equally adept at grooming physician scientists. Dr. Mendelsohn's success had not been that of his friend Ki's in the area of clinical research, although he too had his stellar mentees. Rather, it had been the anticipated success of a thoroughbred, one who shone as brightly and consistently as others expected him to, although he also took risks by launching his career at the University of California at San Diego, a brand-new cancer center director for a brand-new medical school.

Just as Dr. Hong had strengths and qualities that were not necessarily Dr. Mendelsohn's forte, Dr. Mendelsohn brought qualities that were not in Dr. Hong's wheelhouse. Most emphatically, John Mendelsohn was both a stellar and sincere public speaker, one who moved easily in the circles of power. He also was a true renaissance man and a scholar, fluent in the language of literature, opera, and history—always taking time on a trip to visit a bookstore or see a sight—something we experienced first hand. This translated into his interacting with the society of Houston and the world society to spread the word and raise money for cancer research. John positively radiated the importance of the mission, inspiring people to jump on the bandwagon and to build further. Like Waun Ki Hong, John Mendelsohn was focused and detail-oriented, always working with investigators to understand all their data and every intricacy of each figure. Even in difficult times for the institution, he was always sincere and well meaning in wanting to bridge gaps, push the agenda, and focus on the institutional mission. Finally, he had the unabridged optimism of a man who believed that science eventually could overcome the most difficult problem, that it was the marriage of science and medicine that could literally cleave the Gordian knot of cancer. That quality, which he shared with Waun Ki Hong, he conveyed publicly and in the circles of power with a reassurance and purpose that few could match. In both cases, their work helped innumerable patients.

In the final analysis, these 2 men worked collaboratively within a relationship firmly grounded in shared trust and a shared mission to take MDACC to a new plateau. They molded one of the largest, although at the time not most prestigious, clinical cancer centers in the world into an institution with a reputation to match its size. Along with Memorial Sloan Kettering, where Waun Ki Hong trained and John Mendelsohn would later serve as Chair of Cancer Medicine, MDACC became essential in every conversation in the field, whether it involved launching a new drug or device, landing a grant, making a major commitment, or even the most basic element of what institution to choose for the care of a loved one. Before them, R. Lee Clark and Charles A. “Mickey” LeMaistre had done extraordinary work to launch and build the culture of this great institution. But Waun Ki Hong and John Mendelsohn, together for almost 2 decades as allies and co-conspirators, would take MDACC to another level entirely. To watch the 2 of them huddle together and then work a room, plan a project, develop a long-term strategy, and encourage their team was to watch an almost subconscious level of synergy. We will rarely ever see the equal of these 2 remarkable men. Their passings, ironically within days of each other, leave us considerably poorer, but their lessons have enriched our lives and served the cause of patients with cancer everywhere. Their legacies, both separate and joint, will endure for the betterment of generations of physicians, scientists, and, most important, legions of patients with cancer.


John A. Mendelson

Fundamental Research Analyst at Evercore Group LLC

Relationship likelihood: Strong

Fundamental Research Analyst at Evercore Group LLC

Relationship likelihood: Strong

Fundamental Research Analyst at Evercore Group LLC

Relationship likelihood: Strong

Head of Sales, Evercore ISI at Evercore, Inc.

Relationship likelihood: Strong

Former Senior Vice President at Stanford Group Co.

Relationship likelihood: Strong

Executive Chairman, Evercore ISI at Evercore, Inc.

Relationship likelihood: Strong

President, Evercore ISI at Evercore, Inc.

Relationship likelihood: Strong

Former Senior Managing Director & Head of the Tech Strategy Research Team at International Strategy & Investment Group LLC

Relationship likelihood: Strong

Macro Research Analyst at Evercore Group LLC

Relationship likelihood: Strong

Fundamental Research Analyst at Evercore Group LLC

Relationship likelihood: Strong

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.

Princeton University is a vibrant community of scholarship and learning that stands in the nation's service and in the service of all nations. Chartered in 1746, Princeton is the fourth-oldest college in the United States. Princeton is an independent, coeducational, nondenominational institution that provides undergraduate and graduate in struction in the humanities, social sciences, natural sciences and engineering. As a world-renowned research university, Princeton seeks to achieve the highest levels of distinction in the discovery and transmission of knowledge and understanding. At the same time, Princeton is distinctive among research universities in its commitment to undergraduate teaching. Today, more than 1,100 faculty members instruct approximately 5,000 undergraduate students and 2,500 graduate students. The University's generous financial aid program ensures that talented students from all economic backgrounds can afford a Princeton education.

Founded in 1991 by Ed Hyman and Nancy Lazar, International Strategy & Investment Group LLC is a broker/dealer located in New York City. The firm is a subsidiary of Evercore Partners, Inc. (NYSE: EVR). They are also known as ISI Group. The firm specializes in research on the following areas: economics, policy, technical analysis, tech stra tegy, portfolio strategy, quantitative research, integrated oil, accounting and tax policy research, China, machinery, banks, REITs, company surveys and client projects.


John Mendelsohn knew the science. He knew the medicine. He enlisted people to invest in curing and treating cancer

In 2007, I was happily working as a newly minted director of the Vanderbilt-Ingram Cancer Center in Nashville and continuing the tradition that Dr. Hal Moses had established in building a world-class cancer center.

H owever, one day, I received a phone call from Houston, and it was from John Mendelsohn’s office. I knew who he was based on his accomplishments, but didn’t really know him in person.

John said that he was in the process of building an effort to fight cancer on all levels at MD Anderson. To native Texans, such as myself, MD Anderson is the Mecca for loved ones and relatives facing a diagnosis of cancer. (In fact, my great aunt, who lived in our remote rural community, was diagnosed with late-stage colon cancer&mdasha virtual death sentence at the time&mdashbut was able to get an appointment at MD Anderson, where the doctors made a huge impact on her disease.)

Mendelsohn holds the piece of Georgia Etowah marble that was used in the facade of the original MD Anderson Hospital. He and Provost and EVP Raymond DuBois (left) received a plaque from NASA astronaut Tim Kopra, who took the piece of marble with him to the International Space Station. &ndash Photo courtesy of MD Anderson Cancer Center

After several phone conversations, John persuaded me to come down to Houston for a visit. On that visit, John took command of the conversation and shared with me what his plans were with regards to creating a number of new centers and research institutes at MDACC.

He had an uncanny skill for convincing people that he knew what was needed and that simply by joining his team you would be headed in the right direction.

After much thought and consideration, I accepted John’s offer to become the founding provost and executive vice president at MD Anderson later that year.

This decision is one that I will never regret, although it did complicate my family’s plans at the time. On the other hand, it immediately put me on a path of interfacing with all of the major players in the cancer field worldwide.

Mendelsohn with former President George H.W. Bush in 2001. &ndash Photo courtesy of MD Anderson Cancer Center

John Mendelsohn was a 24/7, 365-days-a-year president while at MD Anderson. He never let up. He was passionate about unraveling the mysteries of cancer and worked tirelessly to persuade others to join the crusades of this passion.

He had a remarkable gift for taking highly complex, technical ideas and concepts&mdashe.g., the unique molecular pathway of a particular tumor or the efficacy of a new line of treatment options&mdashand explaining them in ways understandable to people who were not scientists or physicians.

In so doing, he was able to get others to realize that beating back the 200 or more diseases we label &ldquocancer&rdquo would require the lay public and legislators supporting the efforts of researchers and clinicians around the world.

He knew the science. He knew the medicine. Through well thought-out analogies, descriptions and metaphors, he enlisted people to care about and invest in curing and treating cancer.

Millions of lives were affected by Dr. Mendelsohn’s contributions. He leaves quite a legacy. He was truly a great man, inspirational leader, advocate and tireless administrator who unfortunately succumbed to a disease that he fought so hard to cure.

Working with John on a daily basis brought a number of interesting experiences that few would encounter elsewhere. I remember one day being invited to lunch with John and a shuttle astronaut from NASA.

I couldn’t imagine what this meeting was about and how it could have an impact on cancer care or cancer research, but didn’t hesitate to accept the invitation. Turns out that a sample of the Georgia Etowah pink marble that adorned the facade of the original MD Anderson Hospital had been taken up in space on a shuttle mission to the International Space Station by Tim Kopra.

Time magazine, in its Dec. 13, 1954, issue that had Ernest Hemingway on the cover, referred to the impressive new cancer hospital as &ldquothe pink palace of healing,&rdquo because of the color of this marble and the patient-centered care provided at the hospital.

John was very engaging and made sure the Tim understood the importance of that marble being transported up to the space station, while Tim was able to share with us his experiences with the space program and that several family members and loved ones employed at NASA had actually been treated for their cancer at the MD Anderson Hospital, so this mission meant quite a bit to the whole NASA family.

It was great seeing John in action and how he made sure that Tim understood what MD Anderson was all about and why it was so important to have the support from the public and our donors so that we could achieve our mission.

On another occasion, John invited me to join him and others for a visit with former President George H.W. Bush at his home in Kennebunkport.

President Bush was extremely interested and supportive of MD Anderson and a previous chair of the board of visitors. We were warmly welcomed by both Barbara and President Bush.

Immediately, they wanted to know what was going on at MD Anderson and how they could help us to achieve success in our fight against cancer. John was able to communicate with the president in a clear and concise manner that delineated what our biggest current challenges were and how President Bush could help us to overcome those challenges.

Having connections and support from current and previous political leaders at the highest level was crucial for the success of MD Anderson. It became clear to me that John’s skills in managing those relationships and making sure that everyone understood how important our work was and precisely how they could become involved was incredible.

Dr. Mendelsohn’s dedication and work ethic were legend. He always wanted to know more about what we were doing on the research front and how we could make the most impact.

Did we have the right technologies and equipment available to our research team? Were they getting all the support they needed to be successful? Which new recruits were needed to fulfill our mission and be on the cutting edge of science and medicine?

Because of those efforts, MD Anderson was elevated to a higher level in cancer research and cancer care.

Without John, it would have been difficult, if not impossible, for MD Anderson to accomplish its goals in making cancer history.

The author is professor of biochemistry and molecular biology and dean of medicine at the Medical University of South Carolina, former provost and executive vice president at MD Anderson.


Concluding Remarks

Dr. John Mendelsohn's contributions in the development and shaping of the field of targeted and personalized cancer medicine therapy combined with the impact of his lifetime work on improving the lives of patients with cancer will always be cherished by his colleagues and the cancer research community. He was a true pioneer in targeted therapy that always imbued his work with the spirit of team science. Dr. Mendelsohn's work on therapeutic EGFR blocking antibodies either alone or in combination with chemotherapies or radiotherapy has already impacted cancer patient care in significant ways. In addition, his work has also positively impacted the development of antibody-based effective therapeutics against other HER family members and cell surface RTK, at-large, and catalyzed the development of additional strategies to impair the HERs kinase activity. Our training, learning, and professional interactions with Dr. Mendelsohn over the years were meaningful. He has left a deep impact on our scientific philosophy, impacted our career trajectories, helped us stay engaged in science, and passed his values to our trainees. He will be missed by all, but he will continue to live on through his work for a long time to come.


Tonton videonya: Mendelson - Mon Frère